Jefferson says GLP-1 drug costs now outpace inpatient care spending

The economics of GLP-1 coverage have become stark enough at Jefferson that prescription drugs now cost more than inpatient care. For Dr. Joseph Cacchione, the Philadelphia nonprofit system’s chief executive, the math has been hard to ignore as weight-loss drugs like Wegovy and Zepbound spread through its own insurance plan for 65,000 employees.

Jefferson said prescription drugs accounted for about 14% of its insurance spending a decade ago. Last year, that share had climbed to 40%. In 2025, Jefferson’s insurance arm reported about a $180 million loss, and Cacchione said roughly one-third of that was driven by GLP-1 coverage. The pressure was severe enough that Jefferson laid off more than 600 employees as drug benefits crowded out operating dollars.

The system has since tightened access. Jefferson now requires employees to complete diet and lifestyle programs before it will cover GLP-1 drugs for weight loss, a change Cacchione said has already saved about $20 million. “We understand the value of them, but they are putting a big stress on the system,” he said. “The system wants to pay for them. We just can’t afford to pay for them right now.”

The broader insurance fight is over who absorbs the cost when a treatment works, demand surges and budgets do not stretch. Novo Nordisk’s Wegovy carries a list price of $1,349 a month, while Eli Lilly’s Zepbound is listed at $1,086. Employers and insurers typically pay less because of discounts and rebates, but Blue Cross Blue Shield said the net monthly price for employer-sponsored GLP-1 coverage still runs from $617 to $766 per employee. Novo Nordisk has said it will cut Wegovy’s list price by half to $675 starting in 2027, but Cacchione said that would not be enough. “I think they’re going to have to come down more than half,” he said.

The financial pressure is showing up well beyond Jefferson. KFF and the Peterson-KFF Health System Tracker said 34% of non-elderly people with employer-sponsored insurance, about 36.2 million people, have a body mass index that would medically qualify them for a GLP-1 drug. The same research said many employers have found use higher than expected and prescription spending far above plan. Blue Cross Blue Shield, citing Employee Benefit Research Institute modeling, said covering GLP-1s could raise employer premiums by as much as 14%, even under narrow eligibility and perfect adherence.

That is why some employers that first embraced the drugs later pulled back, limiting coverage to diabetes or other specific medical uses. The debate is no longer just about access to a promising treatment. It is about which workers get the benefit, which costs get shifted, and what other care gets squeezed when GLP-1 demand collides with budget reality.